Novo Nordisk A/S (NVO)
47.42
-1.03
(-2.13%)
USD |
NYSE |
Feb 20, 16:00
47.45
+0.03
(+0.06%)
After-Hours: 20:00
Novo Nordisk SG&A Expense (Quarterly) : 2.718B for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Ascendis Pharma A/S | 158.13M |
| Evaxion AS | 0.00 |
| Regeneron Pharmaceuticals, Inc. | 775.00M |
| Viking Therapeutics, Inc. | 11.28M |
| DBV Technologies SA | 8.399M |